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Insulin-like growth factor-I (IGF-I) and II (IGF-II) are regulatory
peptides with a number of biological functions including cell
proliferation, differentiation and anti-apoptosis (Jones and
Clemmons, 1995; Le Roith, 1997). In the circulation, over 95% of
IGF-I and IGF-II is bound to six high-affinity binding proteins
(IGFBPs) (Rajaram et al, 1997). The major binding protein is
IGFBP-3 which binds the IGF ligands forming a 150-kDa ternary
complex with ALS (acid labile subunit). IGFBP-2 is the second
most abundant IGF binding protein, binding IGF-II with a greater
affinity (four-fold) than IGF-I (Clemmons, 1997). Most circu-
lating IGF-I and IGF-II is synthesized in the liver but other tissues,
including epithelial cells, may also contribute (Rajaram et al,
1997). Increased expression of IGF ligands and binding proteins
has been recognized in a variety of human tumours (Macaulay,
1992), and consequently the contribution to the circulation of these
peptides from a site other than that from normal hepatic synthesis
may become significant in neoplastic processes.
In colorectal cancer, increased expression of IGF-II and IGFBP-
2 mRNA has been noted in a number of colonic cancer lines
(Tricoli et al, 1986; Lambert et al, 1992; Singh et al, 1996) and
also, more recently, in human colonic adenocarcinomas (Mishra et
al, 1997; Freier et al, 1999). IGF-I and IGF-II act via the IGF-I
receptor, which is functionally expressed by human colon cancer
lines (Lahm et al, 1994; Adenis et al, 1995). IGF activity may be
further modulated by local levels of IGFBPs (Jones and
Clemmons, 1995), indicating a potential complexity of regulatory
mechanisms. Therefore, the measurement of circulating IGFs and
their binding proteins in patients with cancer may not only reflect
tumour presence but also provide insight into IGF-IGFBP 
inter-relationships at a cellular level.
We have previously reported that serum IGF-II levels are signif-
icantly elevated in healthy individuals (aged 55–64 years) with
adenomas, known precursors of malignancy, found at screening
flexible sigmoidoscopy (Renehan et al, 2000a). Furthermore, in
the same study, elevated serum IGFBP-2 levels were found in
those individuals with large adenomas (³ 1 cm), and both IGF-II
and IGFBP-2 values normalized after adenoma removal, impli-
cating these peptides as potential tumour markers. In the present
study, we have extended this work to examine the relationship
between serum IGF-II and IGFBP-2 in patients with colorectal
cancer compared with a control population of individuals with
normal colonoscopic findings. The relationship between serum
IGF-I and IGFBP-3 and colorectal cancer was also investigated as
there is evidence that circulating IGF-I is positively and IGFBP-3
inversely, and independently, associated with cancer risk for
prostate (Chan et al, 1998), breast (Hankinson et al, 1998) and
colorectal cancer (Ma et al, 1999).
PATIENTS AND METHODS
Patients
Serum samples were collected from 92 patients (79 primary, 13
recurrent, median age = 61 (range 25–93) years) with colorectal
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cancer at the time of presentation. The clinicopathological charac-
teristics of these patients are shown in Table 1. Patients were cate-
gorized into two clinical groups: 50 patients with Dukes A, B or C
tumours who underwent a definitive surgical resection; and 42
patients with advanced disease characterized by distant metastases
at presentation i.e. ‘Dukes D’ (n = 29), or local pelvic recurrence
(n = 13). Additional serum samples were obtained in 27 patients;
6–8 weeks following definitive surgery in 15 patients, and at
variable times (median 5 weeks) during tumour progression in a
further 12 patients. As nutritional status is known to influence
circulatory levels of the IGFs and their binding proteins (Thissen
et al, 1994), cancer patients were also categorized by nutritional
status using the following criteria. Malnutrition was defined when
at least two of the following were present in an individual patient:
malnourished by global subjective assessment; body mass index
less than 20 kg m–2; mean arm circumference < 27 cm in males or
< 26 cm in females; or albumin < 33 mg l–1 (modified from
Hammerlid et al, 1998). The control group comprised serum
samples obtained from 57 individuals (median age = 60 (range
29–87) years, 20 males, 37 females) with normal colonoscopic
findings and no history of previous colorectal neoplasia. The study
was approved by the Local Ethics Committee for South
Manchester Health Authorities.
Clinicopathological parameters
Tumour stage was determined both clinically and on pathological
evaluation. Surgically resected specimens were staged in accor-
dance with Dukes classification (Turnbull et al, 1967) and graded
by the degree of differentiation (well, moderate, poor) in accor-
dance with the WHO classification (Jass and Sobin, 1989). For
primary tumours treated by curative resection, size was the
maximum tumour diameter and the site was classified as right
colon (proximal to splenic flexure), left colon (splenic flexure
to rectosigmoid junction) and rectum. The presence and extent
of advanced disease (all had at least hepatic metastases) was
determined using computerized tomographic (CT) or magnetic
resonance (MR) scanning. Pelvic recurrence was confirmed by a
combination of CT or MR scanning and examination under
anaesthesia with biopsy for histological diagnosis.
Assays
IGF-I was measured, following acid–alcohol extraction, by an
established radioimmunoassay (RIA) using a polyclonal rabbit
antiserum (R557A) raised against purified human IGF-I (Taylor
et al, 1990; Toogood et al, 1998). Serum IGF-II was determined
using a commercially available immunoradiometric assay (IRMA)
kit (DSL, Webster, Texas, USA). IGFBP-2 and IGFBP-3 were
measured using an RIA and IRMA, respectively (DSL). All
samples were determined blind to cancer status and stage, and
were assayed in triplicate. The inter-assay coefficients of variation
(CV) at low, medium and high analyte levels were less than 10%
for all four assays, with intra-assay CVs less than 5%. The sensi-
tivities for IGF-I, IGF-II, IGFBP-2, and IGFBP-3, were 14 mg l–1,
15 mg l–1, 5 mg l–1 and 0.5 mg l–1, respectively. Carcinoembryonic
antigen (CEA) was measured using a two-site (sandwich)
chemilumuninescence system (Chiron Diagnostics, Halstead,
UK). The threshold definition for an elevated CEA level was 5 ng
ml–1, with an analytical sensitivity of 0.5 ng ml–1.
Statistical analysis
As IGF ligands and binding proteins are age- and sex-dependent
(Rajaram et al, 1997), absolute concentrations were converted to
standard deviation scores (SDS) (SDS = (x – X)/SD: x = measured
value, X = mean of normal values for age and sex of an individual,
SD = standard deviation). Normal reference means and standard
deviations were generated from an in-house dataset of 295 healthy
individuals using the above assays (see Appendix for details).
Differences in mean SDS were compared using Students t-test for
independent means, paired t-tests, and one-way ANOVA as appro-
priate. Correlations were described by Pearsons coefficient (r).
Tests were two-sided and a P-value less than 0.05 was considered
to indicate statistical significance using SPSS 9.0 (Superior
Performing Software Systems, Chicago, USA) for computations.
RESULTS
Validation of controls
For the 57 individuals with a normal colonoscopy, IGFBP-3 was
significantly correlated with IGF-I (r = 0.38, P = 0.005) and IGF-
II (r = 0.85, P < 0.001), similar to correlations seen in the normal
reference data (see Appendix). The absolute concentrations for
serum IGF-I, IGF-II, IGFBP-2 and IGFBP-3 in the 57 controls fell
within the 90% predictive intervals as defined by the age–sex
regression equations for normals in 96%, 100%, 98%, and 95% of
values, respectively.
Cases vs controls
When examined for all 92 patients with colorectal cancer, mean
IGF-II SDS were marginally elevated compared with normal
colonoscopy controls (mean ± SEM = 0.46 ± 0.18 vs 0.01 ± 0.09,
P = 0.06). There was no significant trend in IGF-II SDS across the
Dukes stages (one-way ANOVA) but when analysed separately,
mean SDS were significantly elevated in Dukes A (1.43 ± 0.34,
Table 1 Clinicopathological characteristics
Primary Recurrent
(n = 79) (n = 13)
Median age (years) 68 (range 25–93) 58 (range 43–78)
Sex
Male 41 (52) 7
Female 38 (48) 6
Staging
Dukes’ A 12 (15)
Dukes’ B 25 (32)
Dukes’ C 13 (16)
Advanced
distant metastasis (Dukes D)a 29 (37)
local pelvic recurrences 13
Nutritional status
Well-nourished 54 (68) 10
Malnourished 25 (32) 3
Degree of differentionb
Well 10 (20)
Moderate 37 (74)
Poor 3 (6)
Values in parentheses are ranges and percentages; aAll patients with distant
metastases had hepatic lesions, in addition, three patients had pulmonary
and four had intra-abdominal lesions. bTumour differentiation quoted for the
50 patients undergoing primary definitive resection1346 AG Renehan et al
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P < 0.001) and Dukes B (0.93 ± 0.29, P < 0.001) patient groups
(Figure 1A). A number of patients with Dukes C and advanced
disease had greatly elevated IGF-II SDS but overall, the means
were not raised. On the other hand, mean IGFBP-2 SDS was
significantly raised in the total cancer patient group compared with
controls (1.37 ± 0.12 vs 0.17 ± 0.10, P < 0.0001). When consid-
ered by stage of disease, there was a significant trend toward
increasing IGFBP-2 SDS from early to advanced disease (one-way
ANOVA, P < 0.0001), with significantly elevated means in Dukes
B (1.03 ± 0.15, P < 0.001), Dukes C (1.13 ± 0.22, P < 0.001) and
advanced disease (1.89 ± 0.16,  P < 0.0001) compared with
controls (Figure 1B).
For all cases, there were no differences either in mean IGF-I
SDS compared with controls (–0.19 ± 0.13 vs 0.17 ± 0.12, P = 0.2)
or mean IGFBP-3 SDS and controls (0.88 ± 0.20 vs 0.56 ± 0.14,
P = 0.6). When analysed by stage, there were no differences in
mean IGF-I and IGFBP-3 SDS vs controls, with the exception
that mean IGF-I SDS was significantly reduced in patients with
advanced disease in whom malnutrition was prevalent (see below)
(–0.59 ± 0.18 vs 0.17 ± 0.12, P = 0.001).
Effect of nutritional status
Malnutrition was present in six of 34 (18%) Dukes B patients,
three of 13 (23%) Dukes C patients, and 19 of 42 (45%) patients
with advanced disease. For all malnourished cancer patients, mean
SDS were significantly reduced for IGF-I (malnourished vs
controls = –0.87 ± 0.22 vs 0.19 ± 0.15, P < 0.001), IGF-II (–0.48 ±
0.32 vs 1.04 ± 0.20, P < 0.001), and IGFBP-3 (0.06 ± 0.42 vs
1.26 ± 0.23, P = 0.04), but elevated for IGFBP-2 (1.68 ± 0.22 vs
1.16 ± 0.13, P = 0.04). SDS values by nutritional status and disease
status are shown in Table 2.
When the analysis was limited to well-nourished individuals,
patterns of mean IGF-II and IGFBP-2 SDS for cases and controls
were similar to the overall cohort. Of interest, however, after
exclusion of malnutrition, mean IGF-II SDS were more
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Figure 1 IGF-II SDS (A) and IGFBP-2 SDS (B) shown for controls (normal
colonoscopy) and stages in cancer patients (cases). Advanced disease
include metastatic disease and local pelvic recurrences. Well-nourished
cancer patients denoted l; malnourished cancer patients ∆ . Horizontal lines
denote mean SDS for all patients in each subgroup; *P < 0.001 compared
with baseline controls; **P < 0.0001 compared with baseline controls
Table 2 IGF-I, IGF-II, IGFBP-2, and IGFBP-3 by nutritional status and
disease status
SD scores (mean ± SEM)
Well-nourished Malnourisheda P valueb
Number of patients
early/advanced disease 41/23 9/19 –
IGF-I
early (Dukes A, B, C) 0.31 ± 0.20 –0.66 ± 0.22 0.03
advanced disease –0.23 ± 0.29 –1.00 ± 0.29 0.04
IGF-II
early (Dukes A, B, C) 1.12 ± 0.23 0.11 ± 0.35 0.06
advanced disease 0.52 ± 0.36 –0.86 ± 0.40 0.01
IGFBP-2
early (Dukes A, B, C) 0.96 ± 0.14 0.79 ± 0.28 n.s.
advanced disease 1.62 ± 0.22 2.21 ± 0.22 0.07
IGFBP-3
early (Dukes A, B, C) 1.36 ± 0.29 0.77 ± 0.41 n.s.
advanced disease 0.99 ± 0.35 –0.20 ± 0.54 0.06
aSee ‘Patients and Methods’ for criteria defining cancer-related malnutrition;
bStudent t-tests for independent means; n.s. = not significant
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Figure 2 Serial changes in serum IGFBP-2 concentrations in 15 patients
undergoing curative resection and 12 patients with persistent disease. None
of the 15 patients who had curative resection and a repeat blood sample was
malnourished pre-surgery. Patients x, y and z received chemotherapy
between time 1 and 2 with partial tumour response. Patient w had a rectal
tumour debulked with argon ablation between time 1 and 2Elevated IGF-II and binding protein-2 in colorectal cancer 1347
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significantly elevated in patients with Dukes B (1.18 ± 0.34,
P < 0.001), and also significantly elevated in Dukes C patients
(0.63 ± 0.56, wide variance, P = 0.05) compared with colonoscopy
controls.
Relationship of IGF-II and IGFBP-2 and pathological
characteristics
As both serum IGF-II and IGFBP-2 levels were elevated in cancer
cases, we explored their relationships with a number of clinico-
pathological characteristics among the 50 patients who underwent
definitive surgical resection for Dukes A, B and C tumours (Table 3).
There were no associations between IGF-II SDS and tumour size,
differentiation, nodal status, and anatomic site, although there was
a tendency for higher IGF-II SDS in small cancers compared with
larger cancers. In contrast, IGFBP-2 SDS increased with
increasing tumour size (P = 0.01), but similar to IGF-II showed
no associations with degree of differentiation, nodal status or
anatomic site.
Serial IGF-II and IGFBP-2 levels
We analysed serum IGF-II and IGFBP-2 values in 27 cancer
patients before and after, or during treatments. In 15 patients
undergoing curative resection for Dukes A, B and C tumours, there
was a significant reduction in mean IGFBP-2 6–8 weeks following
curative resection (mean ± SEM = 1011 ± 88 vs 860 ± 65 mg l–1,
paired t-test, P = 0.04), but no differences in mean IGF-II values.
In a further 12 patients with persistent or progressive cancer,
follow-up samples demonstrated elevated IGFBP-2 levels in eight
(Figure 2).
Tumour marker characteristics of IGFBP-2
We tested the potential tumour marker characteristics of IGFBP-2
SDS taking an arbitrary cut-off for elevated IGFBP-2 at ³ +2 SDS.
IGFBP-2 SDS were therefore elevated in 26 (28%) cases while
serum CEA was elevated (³ 5 ng ml–1) in 42 (46%). IGFBP-2 SDS
were significantly correlated with CEA (r = 0.49, P < 0.001), but
of the 26 patients with elevated IGFBP-2 SDS, seven had
advanced disease without elevated CEA values, suggesting that
IGFBP-2 SDS may have independent predictive qualities
(quadrant M in Figure 3). We therefore calculated sensitivities,
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Figure 3 Correlation between serum IGFBP-2 (SDS) and CEA
concentrations (log10 transformed). Cut-off points for CEA (5 ng ml–1 or
log10[CEA] = 0.7) and IGFBP-2 (+2 SDS) shown as dotted lines. Of 26
patients with elevated IGFBP-2 SDS), seven had advanced disease but
normal CEA values (quadrant marked M)
Table 3 IGF-II and IGFBP-2 SD scores and various clinicopathological factorsa
SD scores (mean ± SEM)
IGF-II P value IGFBP-2 P valueb
Tumour sizec
< 3.5 cm (n = 16) 1.42 ± 0.41 0.44 ± 0.23
3.5–5.5 cm (n = 18) 1.08 ± 0.38 0.87 ± 0.15
³ 5.5 cm (n = 16) 0.56 ± 0.39 P = n.s. 1.33 ± 0.22 P = 0.01
Differentiation
Well (n = 11) 1.34 ± 0.23 0.79 ± 0.21
Moderate/poor (n = 37/2) 0.98 ± 0.25 P = n.s. 0.85 ± 0.14 P = n.s.
Nodal status
No (n = 37) 1.09 ± 0.24 0.80 ± 0.14
Yes (n = 13) 0.96 ± 0.44 P = n.s. 0.93 ± 0.19 P = n.s.
Site distributiond
Right colon (n = 9) 1.13 ± 0.48 0.85 ± 0.22
Left colon (n = 15) 1.22 ± 0.32 0.79 ± 0.27
Rectum (n = 26) 0.94 ± 0.32 P = n.s. 0.87 ± 0.15 P = n.s.
aBased on the 50 patients undergoing primary definitive resection; bStudent t-tests for independent means and one-way ANOVA,
n.s. = not significant; cTertiles of tumour diameter; dRight colon = proximal to splenic flexure; left colon = splenic flexure to
rectosigmoid junction
Table 4 Tumour marker characteristics of CEA and IGFBP-2
Sensitivity Specificity PPVa NPVb
Metastases alone (n = 29)
CEA (³ 5 mg ml–1) 79% 72% 62% 86%
IGFBP-2 (³ + 2SD) 55% 92% 80% 78%
CEA and/or IGFBP-2 90% 68% 62% 92%
Local pelvic recurrence alone (n = 13)
CEA (³ 5 mg ml–1) 62% 71% 36% 88%
IGFBP-2 (³ + 2SD) 46% 96% 75% 87%
CEA and/or IGFBP-2 77% 69% 40% 92%
Combined metastases and recurrences (n = 42)
CEA (³ 5 mg ml–1) 72% 74% 69% 77%
IGFBP-2 (³ + 2SD) 52% 92% 85% 70%
CEA and/or IGFBP-2 86% 68% 69% 85%
aPPV = positive predictive value; bNPV = negative predictive value.1348 AG Renehan et al
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specificities, positive and negative predictive values for IGFBP-2
SDS alone, CEA alone, and both together, against three main
endpoints: metastasis alone; local recurrence alone; and metastasis
and recurrence combined (Table 4). By itself, the sensitivities for
IGFBP-2 SDS were modest at 55%, 46% and 52%, respectively.
In combination with CEA, however, the sensitivities for the
three endpoints increased substantially to 90%, 77%, and 86%,
respectively.
DISCUSSION
This study has focused on the relationships of serum IGF-II and
IGFBP-2 with colorectal cancer, and found that age–sex adjusted
IGF-II values are significantly raised in patients with early cancers
but seemingly not in advanced disease, and age–sex adjusted
IGFBP-2 values increased significantly from early to advanced
disease, and on average, were two standard deviations greater than
controls in patients with metastatic and recurrent disease. Age–sex
adjusted IGFBP-2 was also associated with tumour size and fell
significantly in patients following curative tumour resection,
suggesting that the circulating IGFBP-2 levels reflect tumour load.
The sensitivities of serum IGFBP-2 alone as a marker of distant
metastasis and/or recurrence were modest but increased substan-
tially in combination with carcinoembryonic antigen (CEA). There
were no associations between serum IGF-I and IGFBP-3, and
the presence of cancer, but all four IGF-related peptides were
significantly influenced by nutritional status.
Two small studies, from the same institute, have previously
reported elevated IGF-II and IGFBP-2 levels in patients with
colorectal cancer measured semi-quantitively from immunoblots
(el Atiq et al, 1994; Baciuchka et al, 1998). In the present study,
the use of radioimmunoassays and immunoradiometric assays
afforded us the opportunity to investigate a large number of cases
and controls, make adjustments for predicted age-and sex-related
changes, and undertake subanalyses to evaluate the influences of
different clinicopathological factors, nutritional status and treat-
ment. Furthermore, the current study design carefully chose indi-
viduals with normal colonoscopic findings as controls, as serum
IGF-II and IGFBP-2 levels may be elevated even in the presence
of occult benign colorectal tumours (Renehan et al, 2000a).
The increase in serum IGF-II observed in patients with Dukes A
and B colorectal cancers extends our observations that serum IGF-
II is significantly raised in individuals with colorectal adenomas
(Renehan et al, 2000a). At first glance, the lack of an IGF-II
increase in patients with more advanced disease appears paradox-
ical. The paradox remained even after adjustment for nutritional
status (malnutrition was prevalent among patients with more
advanced disease and is a negative regulator of IGF-II) and
suggests that there may be a down-regulation or post-transcrip-
tional modification of IGF-II peptide expression with advancing
disease. Consistent with the latter hypothesis, IGF-II immunohis-
tochemical expression is absent in normal colonic epithelium,
almost universally positive in adenomas (Renehan et al, 2000a),
but present in only half of adenocarcinomas examined with high
positivity scores limited to well differentiated cancers (observa-
tions from our laboratory). The relevance of raised serum IGF-II is
unknown, but as IGF-II is both mitogenic and anti-apoptotic, it is
generally perceived to be a factor favouring tumour progression
(Macaulay, 1992). In support of this view, Kawamoto et al (1998)
have observed that IGF-II immunopositivity predicts for poor
prognosis in colorectal cancers.
The finding of raised serum IGFBP-2 in colorectal cancer
patients is in accordance with other reports describing elevated
IGFBP-2 levels in various malignancies including lung (Reeve
et al, 1990), ovary (Kanety et al, 1996), prostate (Cohen et al,
1993; Ho and Baxter, 1997), Wilm’s tumour (Zumkeller et al,
1993) and childhood leukaemia (Muller et al, 1994; Mohnike et al,
1996; Wex et al, 1998). In the absence of a clearly understood
physiological role for IGFBP-2, these collective observations
suggest that this binding protein may have a special role in malig-
nancy. At a tissue level, through sequestration of ligand from its
receptor, the effect of IGFBP-2 on the mitogenic action of IGF-I
and IGF-II is generally considered inhibitory (Jones and
Clemmons, 1995), and this has been shown to be the case in some
IGF-responsive colonic carcinoma cell lines (Hoeflich et al, 1998).
However, Hoeflich and colleagues (2000) have also reported a
stimulatory effect of IGFBP-2 via IGF-I receptor-independent
mechanisms in adenocortical tumour cells, and whether these
pathways exist in colonic cancers is not yet known.
An alternative and attractive hypothesis for the role of increased
IGFBP-2 in malignancy is that it serves as a storage pool for IGF-
II (which binds with greater affinity than IGF-I) in the microenvi-
ronment of tumour cells. It has recently been recognized that an
IGF-II/IGFBP-2 complex may partly bind to the extracellular
matrix (ECM) (Arai et al, 1996) from where IGF-II may be liber-
ated by proteolysis. A serine protease capable of degrading
IGFBP-2 has been described, which leads to a reduction of the IGF
binding capacity and liberation of its ligands into the pericellular
environment (Gockerman and Clemmons, 1995). Based on this
hypothetical model, the increased IGFBP-2 in the circulation may
provide a reservoir for ECM-bound IGF/IGFBP-2 complexes in
the vicinity of tumour cells, and thus the presence of elevated
circulating IGFBP-2 could enhance tumour growth and progression.
We explored the characteristics of serum IGFBP-2 as a potential
tumour marker and its relationship with serum CEA. The sensi-
tivity of 72% for CEA detecting both distant metastases and recur-
rences combined is similar to values (66–85%) found in other
studies (Wang et al, 1994; Wolf and Cohen 1997). Consistent with
other studies (Moertel et al, 1993), we also found that the sensit-
ivity of CEA to detect local pelvic recurrences was lower relative
to its ability to detect distant metastases. Using a cut-off of +2
SDS, the sensitivities of IGFBP-2 alone for the detection of distant
metastases and/or recurrences were modest but increased substan-
tially when combined with CEA. This suggests a potential role for
IGFBP-2 as an adjunct to CEA in monitoring patients with
colorectal cancer. At a time when there is increasing evidence
that intensive surveillance with early detection of recurrent and
metastatic disease offers opportunities to improve survival
(Renehan and O’Dwyer, 2000), prospective studies are now
required to assess the benefits of serial IGFBP-2 monitoring (with
CEA) in patients who have undergone curative treatment for
colorectal cancer.
Whereas the characteristics of serum IGF-II and IGFBP-2 are
best described as tumour markers, the characteristics of serum
IGF-I and IGFBP-3 are best described as predictive for cancer risk.
A number of recent epidemiological studies have demonstrated
associations between circulating IGF-I and IGFBP-3 levels and
cancer risk in various malignancies (Chan et al, 1998; Hankinson
et al, 1998; Ma et al, 1999). Specifically for colorectal cancer, Ma
and colleagues (1999) have reported that high–normal range IGF-I
values and low–normal range IGFBP-3 values predict for sub-
sequent cancer development. We have recently shown that thesame profile (high IGF-I/low IGFBP-3) predicts for ‘high-risk’
adenomas (Renehan et al, 2000b) but the current study was not
specifically designed to assess cancer risk, as confounding factors
such as altered nutritional status were expected (and subsequently
demonstrated) in our cohort. For these reasons, we caution against
drawing conclusions about the relationships of serum IGF-I, IGF-
II and IGFBP-3 and colorectal cancer risk from studies using
cross-sectional designs (Manousus et al, 1999).
This study, together with our previous observations in individ-
uals with colorectal adenomas, have shown that there is a charac-
teristic profile for serum IGF-II and IGFBP-2 from pre-malignant
adenomas through early carcinomas to metastatic colorectal
disease. We have speculated that these distinctive patterns may
provide insight into underlying biological mechanisms. The poten-
tial of serum IGFBP-2 as a tumour marker in colorectal cancer has
been demonstrated, but large prospective studies are required
before definitive conclusions regarding its use in clinical practice
can be drawn.
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APPENDIX
Age- and sex-normal reference means, standard deviations and 90%
predictive ranges for IGF-I, IGF-II, IGFBP-2 and IGFBP-3 were
calculated from regression plots using SigmaPlot 2.0 (Jandel
Scientific Graphing Software, Erkrath, Germany) from measure-
ments in 295 healthy individuals (162 males, 133 females, age 20–90
years). Mean IGF-I, IGF-II and IGFBP-3 levels declined steadily
with age, whereas mean IGFBP-2 levels increased. IGFBP-3 was
strongly correlated with IGF-I (r = 0.77, P < 0.001) and IGF-II (r =
0.76, P< 0.001), while IGFBP-2 was negatively correlated with IGF-
I (r= –0.33, P< 0.001) and IGF-II (r= –0.36, P< 0.001). Mean IGF-
I levels tended to be lower in females compared with males, while the
reverse was seen for IGF-II and IGFBP-3. The sex differences for
IGFBP-2 were small. These relationships were best described mathe-
matically by second-order regression equations (below). The age-
and sex-related changes in our normal reference dataset are similar to
those described in other surveys (Juul et al, 1994; Yu et al, 1999).
Unit Regression equations SD
IGF-I
Males mg l–1 y = (0.0500x – 7.7835)x + 453.9 57
Females mg l–1 y = (0.0478x – 8.2959)x + 471.9 54
IGF-II
Males mg l–1 y = (–0.0717x + 0.7326)x + 904.3 135
Females mg l–1 y = (–0.0300x – 1.0790)x + 921.3 155
IGFBP-2
Males mg l–1 y = (0.2920x – 23.667)x + 926.8 373
Females mg l–1 y = (0.2441x – 15.495)x + 696.1 398
IGFBP-3
Males mg l–1 y = (0.0005x – 0.0823)x + 5.8245 0.38
Females mg l–1 y = (0.0005x – 0.0812)x + 5.8245 0.48